Scholarlink

Background <p>Pulmonary hypertension (PH) is a life-threatening vascular disorder characterized by progressive pulmonary vascular remodeling. Emerging evidence has indicated that long non-coding RNAs (lncRNAs) play vital roles in the pathogenesis of PH. In this study, we aim to clarify the role of lncRNA small nucleolar RNA host gene 18 (<i>Snhg18)</i> in pulmonary vascular remodeling and investigate its underlying mechanisms.</p> Methods <p>Differential gene expression was detected by qRT-PCR and Western blot assays. CCK-8, EdU, transwell assays, and the in vivo pulmonary hypertension model were used to investigate the effect of <i>Snhg18</i> on pulmonary hypertension. Dual-luciferase reporter assay, chromatin immunoprecipitation (ChIP) assay, RNA pull-down, and transcriptome sequencing were employed to explore the mechanism by which <i>Snhg18</i> functions in pulmonary hypertension.</p> Results <p>LncRNA <i>Snhg18</i> is upregulated in pulmonary artery smooth muscle cells (PASMCs) and lung tissues under hypoxic conditions. Inhibition of <i>Snhg18</i> attenuates cell proliferation in vitro and in vivo. Mechanistically, copy number amplification promotes the expression of <i>Snhg18</i> at the genomic level, and the transcription factor Sp1 activates <i>Snhg18</i> transcription by binding to its promoter. Furthermore, <i>Snhg18</i> interacts with the m6A “reader” protein heterogeneous nuclear ribonucleoprotein A2/B1 (Hnrnpa2b1), thus increasing the stability of enolase 3 (Eno3) mRNA in an m6A-dependent manner. The elevation of Eno3 augments glycolysis in PASMCs, thus promoting cell proliferation and vascular remodeling.</p> Conclusions <p>Our study demonstrates the important role of <i>Snhg18</i>/Hnrnpa2b1/Eno3 axis in pulmonary vascular remodeling, and provides a potential novel therapeutic target for PH.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Snhg18 promotes hypoxic pulmonary hypertension by enhancing glycolysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月18日

查看全文
  • Tianyu Qu,
  • Kai Ma,
  • Qiang Du,
  • Chun Zhang,
  • Ziling Shen,
  • Enze Wang,
  • Zhixuan Chen,
  • Pingsheng Chen,
  • Yingying Liu,
  • Ruifeng Zhang

摘要

Background

Pulmonary hypertension (PH) is a life-threatening vascular disorder characterized by progressive pulmonary vascular remodeling. Emerging evidence has indicated that long non-coding RNAs (lncRNAs) play vital roles in the pathogenesis of PH. In this study, we aim to clarify the role of lncRNA small nucleolar RNA host gene 18 (Snhg18) in pulmonary vascular remodeling and investigate its underlying mechanisms.

Methods

Differential gene expression was detected by qRT-PCR and Western blot assays. CCK-8, EdU, transwell assays, and the in vivo pulmonary hypertension model were used to investigate the effect of Snhg18 on pulmonary hypertension. Dual-luciferase reporter assay, chromatin immunoprecipitation (ChIP) assay, RNA pull-down, and transcriptome sequencing were employed to explore the mechanism by which Snhg18 functions in pulmonary hypertension.

Results

LncRNA Snhg18 is upregulated in pulmonary artery smooth muscle cells (PASMCs) and lung tissues under hypoxic conditions. Inhibition of Snhg18 attenuates cell proliferation in vitro and in vivo. Mechanistically, copy number amplification promotes the expression of Snhg18 at the genomic level, and the transcription factor Sp1 activates Snhg18 transcription by binding to its promoter. Furthermore, Snhg18 interacts with the m6A “reader” protein heterogeneous nuclear ribonucleoprotein A2/B1 (Hnrnpa2b1), thus increasing the stability of enolase 3 (Eno3) mRNA in an m6A-dependent manner. The elevation of Eno3 augments glycolysis in PASMCs, thus promoting cell proliferation and vascular remodeling.

Conclusions

Our study demonstrates the important role of Snhg18/Hnrnpa2b1/Eno3 axis in pulmonary vascular remodeling, and provides a potential novel therapeutic target for PH.